First patient dosed in YK012 trial-the world’s first TCE therapy for primary membranous nephropathy
Key Highlights Clinical trial to evaluate the safety and efficacy of YK012 in primary membranous nephropathy Globally, this is the first bispecific CD19-directed CD3 T cell engager immunotherapy for this…